Under the terms of this option agreement, Ascentage Pharma is set to receive 100 million USD from Takeda to acquire the option to license olverembatinib. Ascentage will also be eligible for an option exercise fee and additional potential milestones of up to approximately 1.2 billion USD. Additionally, Ascentage Pharma is expected to receive a minority equity investment from Takeda.
根据该期权协议条款，亚盛医药将获得武田制药支付的1亿美元，以获取olverembatinib的许可期权。亚盛医药还将有资格获得期权行使费和额外的潜在里程碑付款，总额高达约12亿美元。此外，亚盛医药预计还将获得武田制药的少数股权投资。